25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Patent number: 8962553Abstract: The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.Type: GrantFiled: November 19, 2012Date of Patent: February 24, 2015Assignee: Cebix ABInventors: John Wahren, Sheri Barrack, James Callaway, Michelle Mazzoni, Howard Foyt, Mark Daniels
-
Patent number: 8962796Abstract: The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care.Type: GrantFiled: January 31, 2013Date of Patent: February 24, 2015Assignee: Danisco US Inc.Inventors: Neelam S. Amin, Katherine D. Collier, Melodie Estabrook, David A. Estell, Bryan P. Fox, Scott D. Power, Brian F. Schmidt, Gudrun Vogentanz
-
Patent number: 8962569Abstract: Provided herein is tumor suppression composition and methods of making and using the same.Type: GrantFiled: May 25, 2011Date of Patent: February 24, 2015Assignees: The Regeants of the University of California, The United States of America as Represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang
-
Patent number: 8962340Abstract: A real-time portable and rapid detection assay to identify the presence of biologically active toxins such as botulinum toxins. The proteolytic activity of BoNT/A is measured using a peptide cleavage assay, where a fluorescent substrate is cleaved by BoNT/A, resulting in increased fluorescence. This fluorescence can be monitored in real-time using a fluorescence detection instrument, such as a real-time PCR system that has been modified to implement a detection algorithm specific to the identification of the target toxin.Type: GrantFiled: March 15, 2013Date of Patent: February 24, 2015Assignee: SRC, Inc.Inventors: Kenton Arthur Doctor, Stacey Ann Massulik, Frances Louise Stites, Timothy Francis Moshier, Jeffrey Harold Mills, Lisa Helen Chamberlin, Deborah L. Plochocki, Olivia Jennifer Barrett, Huda Sirageldin Suliman
-
Publication number: 20150050640Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.Type: ApplicationFiled: March 14, 2013Publication date: February 19, 2015Inventors: Liudmila Prokunina, Thomas R. O'Brien, Brian Muchmore, Raymond P. Donnelly, Patricia A. Porter-Gill
-
Publication number: 20150050301Abstract: Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergens of house dust mites Der p 1 and Der p 2. Such peptides while providing all potential T cell epitopes are devoid of the three dimensional structure of the original allergen, therefore reducing their ability to bind IgE. As a result increased amounts of COPs can be administered per injection, therefore reducing both the number of injections and the length of the immunotherapy treatment.Type: ApplicationFiled: June 6, 2014Publication date: February 19, 2015Inventors: Alexander Kettner, Christophe Reymond
-
Publication number: 20150050351Abstract: This invention discloses the creation of a novel single ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds comprising a group of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a biocompatible polymer carrying a peptide ligand for targeted delivery and/or encapsulated in ligand targeted polymer nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal biopharmaceutical properties. The stereoisomer peptides carried by the polymer are delivered to cells or tissues to inhibit, suppress, block, antagonize or disrupt, simultaneously and independently, the functional domain of different disease causing proteins.Type: ApplicationFiled: October 23, 2014Publication date: February 19, 2015Inventor: Lucia Irene Gonzalez
-
Publication number: 20150050303Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: ApplicationFiled: August 13, 2014Publication date: February 19, 2015Applicant: ImmusanT, Inc.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
-
Publication number: 20150051153Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.Type: ApplicationFiled: July 13, 2011Publication date: February 19, 2015Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
-
Patent number: 8957184Abstract: The invention relates to chimeric peptides useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors.Type: GrantFiled: March 29, 2010Date of Patent: February 17, 2015Inventors: Angelita Rebollo Garcia, Alphonse Garcia, Xavier Cayla, Issam Arrouss, Katy Billot, Angelique Godet
-
Patent number: 8956878Abstract: The present application is directed to a peptides comprising an a-helix forming-amino acid sequence that binds a heat shock protein. Also included is a polypeptide comprising (a) a first peptide portion that comprises an ?-helix-forming amino acid sequence that binds a heat shock protein; and (b) at least one second peptide portion comprising an antigenic amino acid sequence and/or an a-helix-stabilizing amino acid sequence that increases the interaction of the first peptide portion with the heat shock protein. The present application also includes compositions comprising the peptides and/or polypeptides of present application and uses of the peptides and/or polypeptides of the present application for fractionating substances relevant for discovery, research or clinical analysis from a biological sample and as therapeutics.Type: GrantFiled: March 21, 2012Date of Patent: February 17, 2015Assignees: Atlantic Cancer Research Institute, New England Peptide, Inc.Inventors: Steven Gareth Griffiths, Scott Edwin Lewis
-
Publication number: 20150045281Abstract: The invention relates to a GLP-1 prodrug of the general formula I: R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1 peptide) (Formula I), wherein GLP-1 peptide is GLP-1(8-37) (SEQ ID NO: 1) or an analogue thereof having a maximum of nine amino acid changes as compared to GLP-1(8-37), R1 is lower alkyl, (NHXaa1) is an amino acid, Xaa2 is an amino acid, and (OHis) is a radical of imidazole-lactic acid; or a pharmaceutically acceptable salt, amide, or ester of the prodrug. The invention also relates to specific GLP-1 parent drugs of the general formula II: (HOHis)-(GLP-1 peptide) (Formula II), as well as specific intermediate products.Type: ApplicationFiled: February 26, 2013Publication date: February 12, 2015Inventor: Jens C. Norrild
-
Publication number: 20150045304Abstract: The invention relates to peptides including DEDE(SSD)nDEG indicated by SEQ NO. 1, RRRDEDE(SSD)nDEG indicated by SEQ No. 2, RRRGDEDE(SSD)nDEG indicated by SEQ No. 3, and LKKLKKLDEDE(SSD)nDEG indicated by SEQ NO. 4, wherein n is an integer from 2 to 20. The invention also relates to phosphorylating these peptides at multiple amino acid sites by employing casein kinases. These phosphorylated peptides may be used in various applications such as forming mineralized collagen fibrils and biometic composites for use in tissue repair and regeneration.Type: ApplicationFiled: November 13, 2013Publication date: February 12, 2015Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: ELIA BENIASH, CHARLES S. SFEIR
-
Publication number: 20150045283Abstract: The present invention provides novel PAR lderived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR 1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR 1 and promoting PAR 1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR 1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR 1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.Type: ApplicationFiled: November 7, 2012Publication date: February 12, 2015Inventors: Laurent O. Mosnier, John H. Griffin
-
Publication number: 20150044703Abstract: Some embodiments of the present invention relate to methods and compositions for detecting the presence of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.Type: ApplicationFiled: March 12, 2013Publication date: February 12, 2015Applicant: University of South AlabamaInventors: Michael A. Finan, Rodney P. Rocconi, Lewis K. Pannel
-
Publication number: 20150045535Abstract: The present invention relates to an isolated polynucleotide of the complete chromosome of Bacillus licheniformis SJ1904 (ATCC PTA-7992). The present invention also relates to isolated polynucleotides of the chromosome of Bacillus licheniformis SJ1904 that encode biologically active substances and to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing biologically active substances encoded by the polynucleotides and to methods of using the isolated polynucleotides of the complete chromosome of Bacillus licheniformis SJ1904.Type: ApplicationFiled: August 7, 2013Publication date: February 12, 2015Inventors: Randy Berka, Michael Rey, Preethi Ramaiya
-
Publication number: 20150045536Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.Type: ApplicationFiled: September 5, 2014Publication date: February 12, 2015Inventors: Ludger JOHANNES, Eric TARTOUR, Bruno GOUD, Wolf Herve FRIDMAN
-
Publication number: 20150038419Abstract: The present invention includes a novel protein, also referred to herein as simukunin, that inhibits the function of several physiologically important enzymes. Simukunin is a potent inhibitor of the blood coagulation cascade, inhibiting Factor Xa and functioning as an efficient anticoagulant. Simukunin also inhibits the serine proteases elastase and cathepsin and demonstrates anti-inflammatory properties. Also included are methods of making and using simukunin.Type: ApplicationFiled: May 25, 2012Publication date: February 5, 2015Applicants: THE GOVERNMENT OF USA, as represented by the Secretary of the Dept. of Health & Human Services, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventors: Donald E. Champagne, Hitoshi Tsujimoto, Ivo Francischetti, Michael R. Strand, Michail Kotsyfakis
-
Publication number: 20150037330Abstract: Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation. Methods of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation, are also provided.Type: ApplicationFiled: August 18, 2014Publication date: February 5, 2015Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventors: Toshiaki Kawakami, Yuko Kawakami
-
Publication number: 20150038674Abstract: The present invention relates to the use of GLP-2 analogue in an efficient amount for the production of a drug specific to treat a pulmonary disease which IS caused by oxidative stress, inflammation and/or apoptosis in an organism.Type: ApplicationFiled: October 28, 2013Publication date: February 5, 2015Inventors: Bertan Boran BAYRAK, Fusun OZTAY, Sehnaz BOLKENT, B. Pelin Arda PIRINCCI, Refiye YANARDAG
-
Publication number: 20150038408Abstract: The present invention provides polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 12, 2013Publication date: February 5, 2015Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
-
Publication number: 20150038675Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.Type: ApplicationFiled: February 12, 2013Publication date: February 5, 2015Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
-
Patent number: 8946381Abstract: The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.Type: GrantFiled: February 6, 2007Date of Patent: February 3, 2015Assignees: Phylogica Limited, The McComb Foundation, Inc.Inventors: Mark Fear, Paul Watt, Richard Hopkins, Nadia Milech
-
Publication number: 20150030699Abstract: The invention relates to a chimeric peptide construct comprising a cell penetrating peptide linked to a pro-apoptotic peptide, for use in treating a tumor in combination with an anti-tumor agent, preferably a chemotherapeutic agent.Type: ApplicationFiled: December 27, 2012Publication date: January 29, 2015Inventors: Angelita Rebollo Garcia, Fariba Nemati, Didier Decaudin
-
Publication number: 20150030537Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.Type: ApplicationFiled: August 1, 2014Publication date: January 29, 2015Inventors: Abdellah Sentissi, Douglas B. Jacoby
-
Publication number: 20150031598Abstract: Novel fusion proteins compromising nuclear factor kB essential modulator-binding (NEMO) domain or a fragment thereof and MCoTI-I/II or a fragment thereof, and their use for the treatment of inflammatory diseases and other medical conditions.Type: ApplicationFiled: August 22, 2014Publication date: January 29, 2015Inventors: Nima Shiva, Mark W. Nowak
-
Publication number: 20150031851Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.Type: ApplicationFiled: October 30, 2013Publication date: January 29, 2015Applicant: SANFORD-BUMHAM MEDICAL RESEARCH INSTITUTEInventors: ERKKI RUOSLAHTI, KIMMO PORKA, SVEN CHRISTIAN
-
Publication number: 20150031852Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety.Type: ApplicationFiled: July 27, 2012Publication date: January 29, 2015Applicant: AVELAS BIOSCIENCES, INC.Inventors: Junjie Liu, Jesus Gonzalez
-
Publication number: 20150031633Abstract: The bifunctional peptide is capable of activating collagen synthesis and inhibiting the production of matrix metallo-proteinases. The peptide has a sequence including three peptide parts A, B and C. The first peptide part A corresponds to a hexapeptide repeated at least three times, the part A being capable of bonding to a receptor elastin-binding protein in order to stimulate collagen synthesis. The second peptide part B corresponds to a tetrapeptide capable of acting as a competitive inhibitor of urokinase protease and of being cleaved by said protease. The third peptide part C corresponds to a tripeptide occupying at least one active site of the matrix metallo-proteinases in order to enable inhibition of the proteinases. The present invention further concerns a cosmetic and/or pharmaceutical composition incorporating the bifunctional peptide.Type: ApplicationFiled: January 31, 2013Publication date: January 29, 2015Inventors: William Hornebeck, Joan Attia, Sandrine Lorimier, Frank Antonicelli
-
Publication number: 20150031127Abstract: The present disclosure is directed to the preparation of nanostructures by the encapsulation of a charged compound with individual self-assembled unit nano structures.Type: ApplicationFiled: August 31, 2012Publication date: January 29, 2015Applicant: NORTHWESTERN UNIVERSITYInventors: Samuel I. Stupp, Yves Ruff
-
Publication number: 20150031600Abstract: The present invention relates to designed polypeptide biosurfactants that may be prepared by recombinant technology in commercially useful amounts and purified by simple non-chromatographic methods. The designed polypeptide biosurfactants comprise at least one stimuli-responsive amino acid residue or at least one glutamine or asparagine residue and may be useful in modulating the stability of a foam, alone or in combination with an ?-helical peptide. The designed polypeptide biosurfactant may be useful in the formation and collapse of foams in foods, beverages, pharmaceuticals, personal care products, cosmetics, cleaning products, mineral recovery, bioremediation, oil recovery and laundry products. The designed biosurfactants may also be useful in recombinant production and purification of peptides, polypeptides and proteins.Type: ApplicationFiled: December 14, 2011Publication date: January 29, 2015Applicant: The University of QueenslandInventors: Anton Peter Jacob Middelberg, Mirjana Dimitrijev-Dwyer, Michael Brech
-
Publication number: 20150033408Abstract: Provided is a plant having a desired phenotype and/or desired stress resistance. Provided is a transgenic plant overexpressing a polypeptide that has the activity to control plant morphology or the activity to enhance the environmental stress resistance of plants, wherein the polypeptide(s) is one polypeptide or are a plurality of polypeptides selected from among polypeptides comprising the amino acid sequences represented by SEQ ID NOS: 1-317.Type: ApplicationFiled: March 15, 2013Publication date: January 29, 2015Applicant: RIKENInventors: Kousuke Hanada, Mieko Higuchi, Takeshi Yoshizumi, Kentaro Nakaminami, Masanori Okamoto, Motoaki Seki, Minami Matsui
-
Patent number: 8940861Abstract: The present invention provides uricases and methods of their production and use in reducing the amount of uric acid in a subject. The present invention further provides methods employing a uricase of this invention in the treatment and/or prevention of hyperuricemia, gout, tumor lysis syndrome and/or hypertension in a subject.Type: GrantFiled: April 8, 2011Date of Patent: January 27, 2015Assignee: Georgia Tech Research CorporationInventor: Eric A. Gaucher
-
Patent number: 8940703Abstract: TIR-domain decoy peptides and TIR domain peptides are disclosed, as well as methods of using the peptides in the regulation of toll-like receptor (TLR) activation and signaling.Type: GrantFiled: February 7, 2013Date of Patent: January 27, 2015Assignee: University of Maryland, BaltimoreInventor: Vladimir Toshchakov
-
Patent number: 8940863Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.Type: GrantFiled: April 5, 2013Date of Patent: January 27, 2015Assignees: Stella Pharma CorporationInventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
-
Patent number: 8940862Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.Type: GrantFiled: April 5, 2013Date of Patent: January 27, 2015Assignees: Stella Pharma CorporationInventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
-
Patent number: 8940693Abstract: Fusion protein for immunocastration (Sequences la and Ib) that comprises the primary amino acid sequence of the gonadotrophin-liberating protein fused to a theoretical sequence: Sequence la NH2-QHWSYGLRPGGPPFSGGGGPPFSA-COOH (SEQ ID NO: 1) Sequence Ib NH2-GPPFSGGGGPPFSAQHWSYGLRPG-COOH (SEQ ID NO: 2); DNA sequences coding for said fusion protein; vaccine comprising said fusion protein; use of the fusion protein for mammal immunocastration; process for producing the vaccine; process for preparing the fusion protein that comprises fusing the amino acid sequence of the gonadotrophin-liberating hormone (GnRH-I) to a theoretical glycosilable sequence having immunogenic activity that does not include pathogen or “carrier” protein sequences in its structure.Type: GrantFiled: April 14, 2010Date of Patent: January 27, 2015Assignee: Universidad de ChileInventor: Leonardo Enrique Saenziturriaga
-
Patent number: 8940306Abstract: An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid ? peptide that induces an enhanced immune response. An amyloid ? peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid ? peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid ? peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.Type: GrantFiled: September 5, 2013Date of Patent: January 27, 2015Assignee: The Chemo-Sero-Therapeutic Research InstituteInventors: Junichi Matsuda, Kazuyoshi Kaminaka, Chikateru Nozaki
-
Publication number: 20150023988Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 22, 2015Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA
-
Publication number: 20150025016Abstract: The present invention relates to peptides capable of inhibiting the formation of the complex between the Asf1 histone chaperone and histones H3-H4, and to the use thereof as a drug, particularly for treating cancer.Type: ApplicationFiled: November 16, 2012Publication date: January 22, 2015Inventors: Francoise Ochsenbein, Raphael Guerois, Albane Gaubert, Regis Courbeyrette
-
Publication number: 20150024417Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic ehrlichiosis.Type: ApplicationFiled: August 1, 2014Publication date: January 22, 2015Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile
-
Publication number: 20150025002Abstract: The invention relates to peptides and peptide derivatives based on the naturally occurring peptide xenin. The invention provides a peptide of SEQ ID No. 1 or an analogue thereof which is able to stimulate insulin secretion and which has no more than 7 amino acid substitutions or deletions as compared to the native sequence, the peptide having one or more lysine residues substituted with a lipophilic substituent of 840 carbon atoms, optionally via a spacer. The present invention also provides a peptide of SEQ ID No. 1 or an analogue thereof which is able to stimulate insulin secretion and which has no more than 7 amino acid substitutions or deletions as compared to the native sequence and in which one or more of Lys4, Lys8, Arg11, Lys13, Phe17, Lys20, or Arg21 have been replaced with another amino acid which increases resistance of the peptide to enzymatic degradation. Further provided are molecules and formulations comprising these peptides and therapeutic uses of these peptides.Type: ApplicationFiled: January 14, 2013Publication date: January 22, 2015Inventors: Victor Alan Gault, Nigel Irwin, Peter Flatt
-
Publication number: 20150023974Abstract: The present invention relates to the identification of a TLR2 binding epitope wherein binding of a binding member to the epitope serves to inhibit TLR2 activation and/or signalling. Polypeptide fragments of TLR2 and three-dimensional structures comprising one or more amino acid residues His318, Pro320, Gln321 or Arg321, Tyr323, Lys347, Phe349, Leu371, Glu375, Tyr376 and His398 of TLR2 which define the identified epitope are provided for use in generating binding members. Also provided are binding members which bind to the identified epitope and methods of using same for the treatment and/or prevention of conditions associated with TLR2 activation and/or signalling.Type: ApplicationFiled: March 29, 2013Publication date: January 22, 2015Inventors: Nils Kuklik, Wolf-Dieter Schubert
-
Patent number: 8937047Abstract: Provided herein are methods of reducing liver uptake in vivo of a polypeptide that specifically binds to a target comprising: (a) providing a polypeptide that specifically binds to a target; and (b) substituting at least one basic or at least one neutral amino acid residue of the native polypeptide from step (a) with an acidic amino acid residue to produce a modified polypeptide, wherein the modified polypeptide demonstrates an isoelectric point at least 0.05-0.1 pH points less than the isoelectric point of the native polypeptide. Also provided are polypeptides made using the inventive methods as well as imaging techniques that employ the methods and agents.Type: GrantFiled: December 19, 2007Date of Patent: January 20, 2015Assignee: General Electric CompanyInventors: Michael Ernest Marino, Faisal Ahmed Syud, Jason William Castle, Brian Duh-Lan Lee, Malin Lindborg, Elin Gunneriusson, Christofer Lendel
-
Patent number: 8936807Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.Type: GrantFiled: July 9, 2013Date of Patent: January 20, 2015Assignee: Lipopeptide ABInventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
-
Patent number: 8937153Abstract: The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans.Type: GrantFiled: July 17, 2008Date of Patent: January 20, 2015Assignee: Affibody ABInventors: Lars Abrahmsén, Andreas Jonsson, Jakob Dogan, Per-Åke Nygren
-
Publication number: 20150018518Abstract: The present invention relates, inter alia, to ghrelin analogues and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and/or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.Type: ApplicationFiled: February 1, 2013Publication date: January 15, 2015Applicant: ZEALAND PHARMA A/SInventors: Simon Birksø Larsen, Ditte Riber
-
Publication number: 20150018224Abstract: The invention provides an isolated peptide comprising a lysine 2-hydroxyisobutyrylation site, a lysine 2-hydroxyisobutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 2-hydroxyisobutyrylation in a sample using the reagent.Type: ApplicationFiled: July 15, 2013Publication date: January 15, 2015Inventors: Yingming ZHAO, Lunzhi Dai
-
Publication number: 20150018289Abstract: The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity.Type: ApplicationFiled: January 22, 2014Publication date: January 15, 2015Applicant: IMPERIAL INNOVATIONSInventor: Stephen R. Bloom
-
Patent number: 8933197Abstract: The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: GrantFiled: August 15, 2008Date of Patent: January 13, 2015Assignee: Amunix Operating Inc.Inventors: Willem P. Stemmer, Volker Schellenberger